Stay updated on Efficacy Safety Rituximab + Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Rituximab + Omalizumab Clinical Trial page.

Latest updates to the Efficacy Safety Rituximab + Omalizumab Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 has been added, and the prior funding-status notice (including the lapse in government funding) and the earlier Revision: v3.4.1 entry have been removed.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding/operating status notice and updated the site version from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedGlossary display is now shown on the page. The update adds a QC status label 'Last Update Submitted that Met QC Criteria', a 'No FEAR Act Data' notice, and a new 'Revision: v3.4.0' tag.SummaryDifference0.2%

- Check35 days agoChange DetectedWithdrawn status is displayed for the study, and several regulatory disclosures (FDA-regulated product indicators, IPD sharing plans) have been removed. Related details such as PI/IRB status and regulatory notes are no longer visible.SummaryDifference17%

- Check42 days agoChange DetectedThe only change is a footer revision label updated to Revision: v3.3.4 (replacing v3.3.3); this is a minor, technical update and does not affect study details, data, or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedLocations now include California under Locations. The California Locations entry and HHS Vulnerability Disclosure link were removed, and the page revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Efficacy Safety Rituximab + Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Rituximab + Omalizumab Clinical Trial page.